anti-CD20/anti-CD3 bispecific antibody MBS303

{
  "id": "MLC-T-ONC-010299",
  "term": "anti-CD20/anti-CD3 bispecific antibody MBS303",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody and T-cell engager (TCE) targeting both the tumor-associated antigen (TAA) CD20 and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20/anti-CD3 bispecific antibody MBS303 binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. CD20 is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. MBS303, composed of a 2:1 bispecific antibody structure, binds to CD20 with two arms and CD3 molecule with one arm to increase affinity with tumor cells and decrease the off-target toxicity of T cells.",
  "synonyms": [
    "anti-CD3/anti-CD20 monoclonal antibody MBS303",
    "TCE MBS303",
    "T-cell engager MBS303",
    "anti-CD20/CD3 monoclonal antibody MBS303",
    "anti-CD20/CD3 bispecific antibody MBS303"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd20-anti-cd3-bispecific-antibody-mbs303/"
}